IPO - Cyclerion Therapeutics, Inc.

Form Type: CORRESP

Filing Date: 2025-02-10

Corporate Action: Ipo

Type: New

Accession Number: 000119312525023605

Filing Summary: Cyclerion Therapeutics, Inc. filed a request for acceleration of its Registration Statement on Form S-3 (File No. 333-284690) with the SEC, seeking to have it declared effective by 4:00 p.m. Eastern Time on February 12, 2025. This request is made pursuant to Rule 461, which allows companies to expedite the effectiveness of their registration statements. The company has authorized William Michener from Ropes & Gray LLP to modify or withdraw this request if necessary. The letter was signed by Regina Graul, President and CEO of the company.

Document Link: View Document

Form Type: S-3

Filing Date: 2025-02-04

Corporate Action: Ipo

Type: New

Accession Number: 000119312525020077

Filing Summary: Cyclerion Therapeutics, Inc. is filing an S-3 Registration Statement under the Securities Act of 1933 to offer securities totaling up to $25,000,000. The filing indicates an intention to sell common stock, preferred stock, warrants, and units comprised of these securities at prices to be determined in future prospectus supplements. The company, which became independent through a tax-free spin-off from Ironwood Pharmaceuticals on April 1, 2019, has shifted strategies focusing on non-sGC stimulator assets, especially within CNS therapeutic areas. The company's common stock trades under 'CYCN' on the Nasdaq Capital Market. The filing also mentions prior asset sales and commitments to fund research and development while maintaining compliance with SEC regulations regarding public float restrictions. It provides a detailed caution regarding risks associated with investing in the company's securities.

Document Link: View Document